GREY:IMVIF - Post by User
Comment by
Breakthorough1on Aug 14, 2023 4:13am
76 Views
Post# 35586470
RE:From 86% (then 76%) to 46.2% ORR in PDL1+
RE:From 86% (then 76%) to 46.2% ORR in PDL1+The OS is very good though: 10,1 months ITT; 17,4 months PDL1+. And with justification of MOA: 24,2 months in those patients with ELISpPlot response tu survivin; 24, 2 months in those with injection-site reaction (meaning DPX activity).
The OS is better than that of Loncatusimab even in the ITT population (9'5 months for Lonca), and with bettter safety profile.
The need for time (=money) has killed the company.